内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

缓解2型糖尿病中国专家共识

2021-09-20 中国内分泌相关专家小组（统称） 中国糖尿病杂志. 2021,29(09

2型糖尿病

一、前言2型糖尿病（T2DM）一直被认为是一种遗传因素与环境因素相互作用所致、以高血糖为特征的进展性疾病,需要长期使用降糖药物治疗。但近年来随着T2DM疾病谱的改变和循证医学证据的不断积累,这一认识正

中文标题：

缓解2型糖尿病中国专家共识

发布机构：

中国内分泌相关专家小组（统称）

发布日期：

2021-09-20

简要介绍：

一、前言2型糖尿病（T2DM）一直被认为是一种遗传因素与环境因素相互作用所致、以高血糖为特征的进展性疾病,需要长期使用降糖药物治疗。但近年来随着T2DM疾病谱的改变和循证医学证据的不断积累,这一认识正在逐渐改变。近40年来,我国糖尿病患病率逐年上升,主要原因是生活方式改变带来的超重及肥胖患病率的升高。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2型糖尿病缓解中国专家共识_邹大进.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9ffa81c00219e6d9, title=缓解2型糖尿病中国专家共识, enTitle=, guiderFrom=中国糖尿病杂志. 2021,29(09, authorId=0, author=, summary=一、前言2型糖尿病（T2DM）一直被认为是一种遗传因素与环境因素相互作用所致、以高血糖为特征的进展性疾病,需要长期使用降糖药物治疗。但近年来随着T2DM疾病谱的改变和循证医学证据的不断积累,这一认识正, cover=https://img.medsci.cn/2021929/1632925398886_2020535.jpg, journalId=0, articlesId=null, associationId=666, associationName=中国内分泌相关专家小组（统称）, associationIntro=这是一个统称，其下指南和专家共识均由国内内分泌领域的专家制定。, copyright=0, guiderPublishedTime=Mon Sep 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">一、前言2型糖尿病（T2DM）一直被认为是一种遗传因素与环境因素相互作用所致、以高血糖为特征的进展性疾病,需要长期使用降糖药物治疗。但近年来随着T2DM疾病谱的改变和循证医学证据的不断积累,这一认识正在逐渐改变。近40年来,我国糖尿病患病率逐年上升,主要原因是生活方式改变带来的超重及肥胖患病率的升高。</span></p>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2052, guiderKeyword=2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=61432, appHits=544, showAppHits=0, pcHits=2158, showPcHits=60888, likes=4, shares=75, comments=24, approvalStatus=1, publishedTime=Wed Sep 29 22:55:37 CST 2021, publishedTimeString=2021-09-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Sep 29 22:25:05 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:56:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2型糖尿病缓解中国专家共识_邹大进.pdf)])
2型糖尿病缓解中国专家共识_邹大进.pdf
下载请点击：
评论区 (21)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2178890, encodeId=511a21e8890a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99fa6392351, createdName=ms5000000614483588, createdTime=Tue Jan 02 22:50:36 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240952, encodeId=b9a51240952d0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:39:20 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240950, encodeId=4ea01240950c7, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:38:43 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184808, encodeId=9678118480844, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e86468795, createdName=ms3000001571005053, createdTime=Sun Jan 16 12:32:59 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180864, encodeId=ad88118086486, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:39:22 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2024-01-02 ms5000000614483588 来自广东省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2178890, encodeId=511a21e8890a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99fa6392351, createdName=ms5000000614483588, createdTime=Tue Jan 02 22:50:36 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240952, encodeId=b9a51240952d0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:39:20 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240950, encodeId=4ea01240950c7, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:38:43 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184808, encodeId=9678118480844, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e86468795, createdName=ms3000001571005053, createdTime=Sun Jan 16 12:32:59 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180864, encodeId=ad88118086486, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:39:22 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-08-25 ms3000000453192874

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2178890, encodeId=511a21e8890a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99fa6392351, createdName=ms5000000614483588, createdTime=Tue Jan 02 22:50:36 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240952, encodeId=b9a51240952d0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:39:20 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240950, encodeId=4ea01240950c7, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:38:43 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184808, encodeId=9678118480844, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e86468795, createdName=ms3000001571005053, createdTime=Sun Jan 16 12:32:59 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180864, encodeId=ad88118086486, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:39:22 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-08-25 ms3000000453192874

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2178890, encodeId=511a21e8890a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99fa6392351, createdName=ms5000000614483588, createdTime=Tue Jan 02 22:50:36 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240952, encodeId=b9a51240952d0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:39:20 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240950, encodeId=4ea01240950c7, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:38:43 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184808, encodeId=9678118480844, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e86468795, createdName=ms3000001571005053, createdTime=Sun Jan 16 12:32:59 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180864, encodeId=ad88118086486, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:39:22 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-16 ms3000001571005053

    #学习#一起学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2178890, encodeId=511a21e8890a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99fa6392351, createdName=ms5000000614483588, createdTime=Tue Jan 02 22:50:36 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240952, encodeId=b9a51240952d0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:39:20 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240950, encodeId=4ea01240950c7, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c98133953, createdName=ms3000000453192874, createdTime=Thu Aug 25 15:38:43 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184808, encodeId=9678118480844, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e86468795, createdName=ms3000001571005053, createdTime=Sun Jan 16 12:32:59 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180864, encodeId=ad88118086486, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:39:22 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-05 坚定的心

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

基层2型糖尿病胰岛素应用专家共识

中华医学会(CMA,Chinese Medical Association) · 2021-07-20

中国2型糖尿病防治指南(2020年版)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2021-04-02

2型糖尿病基层合理用药指南

中华医学会临床药学分会 · 2021-06-02

成人2型糖尿病患者口服降糖药物三联优化方案（二甲双胍+二肽基肽酶4抑制剂+钠-葡萄糖共转运蛋白2抑制剂）中国专家共识

中国研究型医院学会(CRHA,Chinese Research Hospital Association) · 2021-08-20

中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2021-07-30

2021 ABCD建议：非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病

暂未更新 · 2021-05-02

拓展阅读

2014 ADS立场声明：2型糖尿病血糖管理法则

澳大利亚糖尿病协会(ADS,Australian Diabetes Society) · 2014-12-11

2015 AHA/ADA科学声明：成人2型糖尿病患者心血管疾病的预防（更新版）

美国糖尿病学会(ADA,American Diabetes Association) · 2015-08-05

2015 ADA/AADE/AND联合声明：2型糖尿病的自我管理教育和支持

美国糖尿病学会(ADA,American Diabetes Association) · 2015-06-05

2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识（2015年更新版）

中国医师协会内分泌代谢科医师分会 · 2016-06-30

2013 中国2型糖尿病防治指南（2013年版）

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2014-08-16

2016 临床实践指南：成人2型糖尿病患者的预防，早期识别，诊断，管理以及随访

国外内分泌相关专家小组（统称） · 2016-06-30